Compare VENUS REMEDIES with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AUROBINDO PHARMA VENUS REMEDIES/
AUROBINDO PHARMA
 
P/E (TTM) x -1.5 11.0 - View Chart
P/BV x 0.1 2.4 4.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 VENUS REMEDIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
AUROBINDO PHARMA
Mar-18
VENUS REMEDIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126809 15.6%   
Low Rs61504 12.1%   
Sales per share (Unadj.) Rs301.8281.1 107.4%  
Earnings per share (Unadj.) Rs-24.941.4 -60.1%  
Cash flow per share (Unadj.) Rs2.550.9 5.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs293.3199.4 147.1%  
Shares outstanding (eoy) m12.34585.88 2.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 13.3%   
Avg P/E ratio x-3.815.9 -23.7%  
P/CF ratio (eoy) x36.712.9 284.8%  
Price / Book Value ratio x0.33.3 9.7%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m1,154384,630 0.3%   
No. of employees `0000.917.3 5.3%   
Total wages/salary Rs m39321,308 1.8%   
Avg. sales/employee Rs Th4,026.19,500.7 42.4%   
Avg. wages/employee Rs Th425.01,229.4 34.6%   
Avg. net profit/employee Rs Th-331.81,397.9 -23.7%   
INCOME DATA
Net Sales Rs m3,724164,666 2.3%  
Other income Rs m231,020 2.2%   
Total revenues Rs m3,747165,686 2.3%   
Gross profit Rs m39537,718 1.0%  
Depreciation Rs m3385,580 6.1%   
Interest Rs m354777 45.6%   
Profit before tax Rs m-27532,380 -0.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m328,183 0.4%   
Profit after tax Rs m-30724,229 -1.3%  
Gross profit margin %10.622.9 46.3%  
Effective tax rate %-11.525.3 -45.4%   
Net profit margin %-8.214.7 -56.0%  
BALANCE SHEET DATA
Current assets Rs m2,638121,878 2.2%   
Current liabilities Rs m2,30586,806 2.7%   
Net working cap to sales %8.921.3 42.0%  
Current ratio x1.11.4 81.5%  
Inventory Days Days135130 104.3%  
Debtors Days Days4668 67.8%  
Net fixed assets Rs m4,87181,037 6.0%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m3,496116,218 3.0%   
Net worth Rs m3,619116,804 3.1%   
Long term debt Rs m1,3744,512 30.5%   
Total assets Rs m7,509211,052 3.6%  
Interest coverage x0.242.7 0.5%   
Debt to equity ratio x0.40 983.1%  
Sales to assets ratio x0.50.8 63.6%   
Return on assets %0.611.8 5.3%  
Return on equity %-8.520.7 -40.9%  
Return on capital %1.627.4 5.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m080,727 0.0%   
Fx outflow Rs m51734,700 1.5%   
Net fx Rs m-51746,027 -1.1%   
CASH FLOW
From Operations Rs m51419,548 2.6%  
From Investments Rs m-123-19,570 0.6%  
From Financial Activity Rs m-3878,642 -4.5%  
Net Cashflow Rs m48,922 0.0%  

Share Holding

Indian Promoters % 32.9 54.1 60.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.3%  
FIIs % 0.6 27.7 2.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.2 651.0%  
Shareholders   20,121 69,601 28.9%  
Pledged promoter(s) holding % 36.4 8.6 424.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS